Use of Bacteriophages to Prevent, Diagnose, and Treat Diseases

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

Part A. Three lines of investigations are being pursued currently. 1. Use of bacteriophages in treating human diseases because of bacterial infections. We are currently dealing with infections caused by Klebsiella. We have succeeded in defining bacteriophage cocktails that take care of bacteriophage resistance that arises during infection processes. 2. We have succeeded in engineering Klebsiella phages to have multiple tails to increase the host range of a phage to be capable of infecting and killing multiple hosts species. 3. We have succeeded to construct a T7 bacteriophage derivative in which we cloned a peptide antibiotic gene (AMP), which when infects a given host also produces vast amount of the antibiotic. This enables the phage to kill by the action of AMP any mutant bacterial host which becomes resistant to phage. However the expression of AMP has been poor, which does not kill phage resistant hosts. But when the AMP expression is covalently linked to a soluble protein, the expression was reasonable. These findings encourages us to pursue the process further. Part B. We are using our previously developed phage display technology using bacteriophage Lambda to make vaccines against infectious diseases as well as against cancer. We already constructed displaying potential antigenic peptides and proteins of CLL leukemia, malaria and Covid 19 virus. We invested a lot of time in engineering, purifying, validating, and testing the authenticity of multiple phage constructs that could potentially be developed as a phage-based vaccine for COVID-19, CLL, and malaria. We have also performed several experiments and analyzed data on testing phage-based vaccines in a mouse model to generate immunity against COVID-19 and CLL. We are currently working in the future experimental plan to demonstrate the efficacy of phage-based COVID-19 vaccine.